Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963832 | 0.88 | ALDH1A1 (0.36) | GPR119TSHRALDH1A1GAALMNA | |
| SCHEMBL22015110 | 0.84 | ALDH1A1 (0.36) | GPR119TSHRALDH1A1GAALMNA | |
| SCHEMBL22015101 | 0.82 | ALDH1A1 (0.35) | GPR119RETTSHRALDH1A1GAA | |
| SCHEMBL22015096 | 0.82 | ALDH1A1 (0.35) | GPR119RETTSHRALDH1A1GAA | |
| SCHEMBL24208970 | 0.82 | ALDH1A1 (0.35) | GPR119RETTSHRALDH1A1GAA | |
| SCHEMBL22015798 | 0.82 | ALDH1A1 (0.35) | GPR119RETTSHRALDH1A1GAA | |
| SCHEMBL21963856 | 0.81 | GPR119 (0.36) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL31235483 | 0.78 | GPR119 (0.53) | GPR119RETTSHRALDH1A1GAA | |
| SCHEMBL24209017 | 0.77 | CA12 (0.36) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL21963853 | 0.72 | ALDH1A1 (0.43) | TSHRALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | GPR119 1531/4885CA12 4334/4885CA1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.